|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 10,406,172: Scope, Claims, and Landscape
United States Patent 10,406,172, granted on September 3, 2019, to Bristol-Myers Squibb Company, covers pharmaceutical compositions containing nanodrug particles. The patent's claims focus on specific formulations of these particles designed for enhanced drug delivery and therapeutic efficacy. The asserted patent landscape indicates a competitive environment for nanodrug technologies, with multiple entities holding patents in related areas.
What is the Core Technology Protected by US Patent 10,406,172?
The patent protects pharmaceutical compositions comprising nanodrug particles. These particles are characterized by a specific particle size distribution and the presence of a surfactant. The core technology aims to improve the solubility, bioavailability, and targeted delivery of active pharmaceutical ingredients (APIs).
Claim Scope and Limitations
The patent's claims define the boundaries of the protected technology. Key claims outline the composition of the nanodrug particles and the processes for their preparation.
-
Claim 1 is a central independent claim. It defines a pharmaceutical composition that includes:
- Nanodrug particles having a weight-mean particle size of less than 1000 nanometers.
- At least one surfactant selected from a defined list, present in a specific weight ratio relative to the API.
- A pharmaceutically acceptable carrier.
-
Dependent Claims further refine the scope by specifying:
- Particle size ranges, for example, a weight-mean particle size of less than 500 nanometers.
- Specific surfactants and their concentrations.
- Types of APIs that can be formulated, including small molecule drugs and biologics.
- Dosage forms, such as injectable suspensions.
-
Process Claims may cover methods of preparing these nanodrug particles, such as high-pressure homogenization or milling techniques.
The limitations within these claims, such as the specific particle size and surfactant requirements, are critical for determining infringement. Variations outside these parameters may not fall under the patent's protection.
What is the Asserted Prior Art and Its Impact?
Prior art refers to existing knowledge or inventions that predate the patent filing. The examination process for patent 10,406,172 involved assessing prior art to establish novelty and non-obviousness.
Key Prior Art Considerations
- Existing Nanoparticle Formulations: Before this patent, various nanoparticle drug delivery systems were known. Prior art would include patents and publications describing liposomes, polymeric nanoparticles, and solid lipid nanoparticles. The patent examiners would have evaluated if the claimed nanodrug particles offered a distinct advantage or were a non-obvious variation.
- Surfactant Use in Drug Delivery: The use of surfactants to improve drug solubility and formulation stability is a well-established practice. The patent’s novelty likely hinges on the specific combination of surfactant type, concentration, and the resulting particle characteristics (size, stability) in conjunction with particular APIs.
- Particle Size Reduction Techniques: Methods for reducing particle size, like milling and homogenization, were also known. The patent's novelty might reside in applying these techniques to achieve the specific nanodrug particle characteristics claimed, or in the unique structure of the resulting particles.
The impact of prior art is to define the boundaries of what is patentable. If a similar composition or method was already publicly disclosed, the patent might be deemed invalid or its claims narrowed.
What is the Competitive Patent Landscape for Nanodrug Technologies?
The field of nanodrug delivery is characterized by active research and development, leading to a crowded patent landscape. Bristol-Myers Squibb's patent exists within this broader ecosystem.
Key Players and Their IP
Several pharmaceutical companies and research institutions hold patents related to nanodrug formulations, manufacturing processes, and specific applications.
- Major Pharmaceutical Companies: Companies like Pfizer, Novartis, Merck, and Johnson & Johnson have significant patent portfolios in drug delivery systems, including nanotechnology. Their patents may cover different types of nanoparticles, conjugation strategies, or therapeutic areas.
- Biotechnology Firms: Smaller, specialized biotech companies often focus on novel drug delivery platforms, including advanced nanocarriers for targeted therapies or enhanced drug release.
- Academic Institutions: Universities and research centers frequently publish foundational research and secure patents on novel nanodrug concepts, which are often licensed to commercial entities.
The landscape can be analyzed through various lenses:
- Platform Technologies: Patents covering broad classes of nanocarriers (e.g., all liposomal formulations, all polymeric micelles) versus patents for specific formulations of a particular API.
- Therapeutic Area Focus: Patents targeting nanodrugs for oncology, infectious diseases, autoimmune disorders, or other specific medical fields.
- Manufacturing Processes: Patents on novel or improved methods for synthesizing or characterizing nanodrug particles.
Potential for Overlap and Infringement
The existence of patent 10,406,172 suggests Bristol-Myers Squibb has secured protection for its specific nanodrug composition. Competitors developing nanodrugs that fall within the scope of its claims could face infringement risks.
- Claim Mapping: Infringement analysis involves "claim mapping," where the features of a competitor's product or process are compared to each element of the patent's claims. If all elements of a claim are found in the competitor's offering, literal infringement may occur.
- Doctrine of Equivalents: Even if a competitor's product does not literally infringe, it may infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
Conversely, Bristol-Myers Squibb itself must navigate the patents of others when developing and commercializing its nanodrug products. Freedom-to-operate analyses are crucial for all parties in this space.
How Does Patent 10,406,172 Relate to Specific Drugs or Therapeutic Areas?
While patent 10,406,172 describes a pharmaceutical composition, its specific application is not inherently limited to a single drug or therapeutic area within the patent text itself. However, its practical relevance is often tied to the innovator drugs developed by Bristol-Myers Squibb.
Potential Drug Applications
- Oncology: Many nanodrug technologies are developed to improve the delivery and efficacy of cancer therapeutics, aiming for targeted delivery to tumor sites and reduced systemic toxicity. Bristol-Myers Squibb has a significant presence in oncology, making this a likely area of application.
- Immunology and Inflammation: Nanoparticles can be engineered to deliver immunomodulatory agents or reduce inflammation at specific sites.
- Cardiovascular Diseases: Targeted delivery of drugs to damaged heart tissue or specific vascular sites could be facilitated by nanodrug formulations.
The patent's value is realized when it protects a successful drug. Without knowing the specific APIs formulated into the nanodrug particles covered by this patent by Bristol-Myers Squibb, it is difficult to pinpoint exact drug targets. However, the underlying technology addresses common challenges in drug formulation and delivery that are broadly applicable across various therapeutic categories.
What are the Key Features of the Nanodrug Particles Claimed?
The patent defines specific characteristics of the nanodrug particles that are crucial for their protective scope.
Compositional and Physical Attributes
- Particle Size: A primary defining feature is the weight-mean particle size, specified as being less than 1000 nanometers. This size range is critical for many nanodelivery applications, influencing cellular uptake, circulation time, and tissue penetration. Many dependent claims narrow this further, for example, to less than 500 nanometers.
- Surfactant Inclusion: The presence and type of surfactant are vital. The patent lists specific surfactants or classes of surfactants that must be present. The surfactant plays a role in stabilizing the nanoparticles, preventing aggregation, and potentially aiding in formulation.
- API Integration: The nanodrug particles encapsulate or incorporate an active pharmaceutical ingredient. The patent may specify limitations on the type of API (e.g., small molecule, biologic) or its physical state within the particle.
- Solid Form: The patent may describe the nanodrug particles as being in an amorphous or crystalline solid state, which can impact stability and drug release profiles.
These features collectively define the unique nanodrug composition protected by the patent. Any formulation that replicates these key characteristics, particularly the specific particle size and surfactant requirements, would be subject to scrutiny for potential infringement.
What is the Duration of Patent Protection?
The duration of patent protection dictates the period during which the patent holder has exclusive rights to the invention.
Patent Term and Extensions
- Standard Term: In the United States, utility patents typically have a term of 20 years from the filing date. Patent 10,406,172 was filed on December 19, 2016, and granted on September 3, 2019. Therefore, its standard expiration date is December 19, 2036.
- Patent Term Adjustment (PTA): The America Invents Act (AIA) allows for Patent Term Adjustment to compensate for delays during the USPTO's examination process. The exact PTA for this patent would be calculated based on specific USPTO actions and applicant responses.
- Patent Term Extension (PTE): For pharmaceutical patents, the Hatch-Waxman Act allows for Patent Term Extension to recover some of the patent term lost during regulatory review by the Food and Drug Administration (FDA). If this patent covers a drug product that underwent FDA approval, it may be eligible for PTE. The length of PTE is generally up to five years, with possible extensions for certain drugs.
The effective market exclusivity period may extend beyond the standard 20-year term due to these adjustments and extensions, providing a longer window for the patent holder to recoup R&D investments.
Key Takeaways
- US Patent 10,406,172 protects pharmaceutical compositions containing nanodrug particles with a weight-mean particle size under 1000 nanometers, incorporating specific surfactants.
- The patent's claims focus on the precise compositional and physical attributes of these nanodrug particles, defining its scope.
- The competitive landscape for nanodrug technologies is active, with numerous players holding patents on related formulations and processes, necessitating careful freedom-to-operate assessments.
- Potential applications of the protected technology span various therapeutic areas, particularly those where enhanced drug delivery and efficacy are critical, such as oncology.
- The standard patent term for 10,406,172 extends to December 19, 2036, with potential for extensions through PTA and PTE.
Frequently Asked Questions
-
What is the primary limitation on the particle size described in claim 1 of US Patent 10,406,172?
Claim 1 specifies a weight-mean particle size of less than 1000 nanometers.
-
Can a formulation with a particle size of 1100 nanometers infringe US Patent 10,406,172?
Based on literal interpretation of claim 1, a formulation with a particle size of 1100 nanometers would likely not infringe, as it falls outside the specified "less than 1000 nanometers" limitation. However, the doctrine of equivalents could still apply if the larger particle size performs substantially the same function in substantially the same way to achieve substantially the same result.
-
Does US Patent 10,406,172 claim a specific drug molecule?
The patent claims pharmaceutical compositions containing nanodrug particles. While it specifies the characteristics of the particles and the presence of an active pharmaceutical ingredient (API), it does not claim a specific API molecule itself unless that API is intrinsically linked to the described nanodrug formulation structure in a dependent claim. The patent is primarily focused on the formulation technology.
-
What is the significance of the surfactant requirement in the patent claims?
The surfactant is a critical component of the claimed nanodrug particles. Its inclusion, in combination with the specified particle size and carrier, is essential for defining the protected composition and likely contributes to the enhanced properties (e.g., stability, solubility) of the nanodrug formulation.
-
How can one determine if their nanodrug formulation infringes US Patent 10,406,172?
A comprehensive freedom-to-operate analysis is required. This involves a detailed claim construction and mapping exercise, comparing each element of the patent's claims against the specific characteristics, composition, and manufacturing process of the formulation in question, considering both literal infringement and the doctrine of equivalents.
Citations
[1] Bristol-Myers Squibb Company. (2019). US Patent 10,406,172 B2. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
